In the first quarter of 2019, bluebird bio (NASDAQ: BLUE) was flying high, with the stock soaring more than 60%. The second quarter, however, has been a different story for the biotech. Bluebird has given up much of its gain, although shares are still up around 20% year to date.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,